1
|
Zurak D, Vlajsović D, Duvnjak M, Salajpal K, Kljak K. Factors affecting starch digestibility rate of maize grain in poultry. WORLD POULTRY SCI J 2023. [DOI: 10.1080/00439339.2023.2163043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- D. Zurak
- Department of Animal Nutrition, University of Zagreb Faculty of Agriculture, Zagreb, Croatia
| | - D. Vlajsović
- Department of Animal Nutrition, University of Zagreb Faculty of Agriculture, Zagreb, Croatia
| | - M. Duvnjak
- Department of Animal Nutrition, University of Zagreb Faculty of Agriculture, Zagreb, Croatia
| | - K. Salajpal
- Department of Animal Science, University of Zagreb Faculty of Agriculture, Zagreb, Croatia
| | - K. Kljak
- Department of Animal Nutrition, University of Zagreb Faculty of Agriculture, Zagreb, Croatia
| |
Collapse
|
2
|
Stojsavljevic-Shapeski S, Virovic-Jukic L, Tomas D, Duvnjak M, Tomasic V, Hrabar D, Kralj D, Budimir I, Barsic N, Ljubicic N. Expression of adipokine ghrelin and ghrelin receptor in human colorectal adenoma and correlation with the grade of dysplasia. World J Gastrointest Surg 2021; 13:1708-1720. [PMID: 35070075 PMCID: PMC8727187 DOI: 10.4240/wjgs.v13.i12.1708] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/20/2021] [Accepted: 11/03/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Ghrelin is an adipokine that plays an important role in energy balance. Expression of ghrelin and ghrelin receptor has been investigated in different tissues and tumors. Studies regarding expression of ghrelin and ghrelin receptor in colorectal tumors are scarce and no data on expression of ghrelin and its receptor in colorectal adenomas has been published. Ghrelin and ghrelin receptor were highly expressed in colon carcinoma cells while expression was decreased in less differentiated tumors, presuming that ghrelin might be important in early phases of tumorigenesis.
AIM To investigate the expression of ghrelin and ghrelin receptor in human colorectal adenomas and adjacent colorectal tissue.
METHODS In this prospective study (conducted from June 2015 until May 2019) we included 92 patients (64 male and 28 female) who underwent polypectomy for colorectal adenomas in the Department of Gastroenterology and Hepatology, “Sestre milosrdnice” Clinical Hospital Center in Zagreb, Croatia. After endoscopic removal of colorectal adenoma, an additional sample of colon mucosa in the proximity of the adenoma was collected for pathohistological analysis. Adenomas were graded according to the stage of dysplasia, and ghrelin and ghrelin receptor expression were determined immunohistochemically in both adenoma and adjacent colon tissue using the polyclonal antibody for ghrelin (ab150514, ABCAM Inc, Cambridge, United States) and ghrelin receptor (ab48285, ABCAM Inc, Cambridge, United States). Categorical and nominal variables were described through frequencies and proportions and the difference between specific groups were analyzed with Fisher’s and Fisher-Freeman-Halton’s method respectively. Spearman's rank correlation coefficient was determined for correlation of expression of ghrelin and ghrelin receptor in adenoma and adjacent colon tissue with the grade of adenoma dysplasia.
RESULTS Among 92 patients with colorectal adenoma 43 had adenomas with high-grade dysplasia (46.7%). High expression of ghrelin was 7 times more common in high-grade adenoma compared to low-grade adenomas (13.95% to 2.04%, P = 0.048), while the expression of ghrelin in adjacent colon tissue was low. We found no correlation between ghrelin receptor expression in adenoma and adjacent colon tissue and the grade of colorectal adenoma dysplasia. The most significant correlation was found between ghrelin and ghrelin receptor expression in adenomas with high-grade dysplasia (rho = 0.519, P < 0.001).
CONCLUSION Ghrelin and ghrelin receptor are expressed in colorectal adenoma and adjacent tissue with ghrelin expression being more pronounced in high grade dysplasia as a possible consequence of increased local synthesis.
Collapse
Affiliation(s)
- Sanja Stojsavljevic-Shapeski
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
| | - Lucija Virovic-Jukic
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
- Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| | - Davor Tomas
- Ljudevit Jurak Department of Pathology, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| | - Marko Duvnjak
- Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| | - Vedran Tomasic
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
| | - Davor Hrabar
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
- Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| | - Dominik Kralj
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
| | - Ivan Budimir
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
| | - Neven Barsic
- Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
| | - Neven Ljubicic
- Division of Gastroenterology, Department of Internal Medicine, «Sestre Milosrdnice» University Hospital Center, Zagreb 10000, Croatia
- Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| |
Collapse
|
3
|
Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021; 9:51-59. [PMID: 33604255 PMCID: PMC7868699 DOI: 10.14218/jcth.2020.00057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 09/18/2020] [Accepted: 10/21/2020] [Indexed: 12/12/2022] Open
Abstract
Patients with nonalcoholic steatohepatitis (NASH) are at higher risk of progression to advanced stages of fibrosis, cirrhosis, hepatocellular carcinoma and other end-stage liver disease complications. When addressing treatment of NASH, we have limited approved options, and the mainstay of therapy is lifestyle intervention. Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH to improve insulin sensitivity, glucose and lipid metabolism, to inhibit de novo lipogenesis and delivery of lipids to the liver, and to influence apoptosis, inflammation and fibrogenesis. Although NASH is a multifactorial disease, in the future we could identify the predominating pathological mechanism and, by choosing the most appropriate specific medication, tailor the treatment for every patient individually.
Collapse
Affiliation(s)
| | - Marko Duvnjak
- Polyclinic Duvnjak, Zagreb, Croatia
- University of Applied Health Science, Zagreb, Croatia
- Correspondence to: Marko Duvnjak, Polyclinic Duvnjak, Kukuljeviceva 2, Zagreb 10000, Croatia. Tel: +38-5989838930, E-mail:
| | - Lucija Virovic-Jukic
- Department of Gastroenterology and Hepatology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Davor Hrabar
- Department of Gastroenterology and Hepatology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Lea Smircic Duvnjak
- University of Applied Health Science, Zagreb, Croatia
- Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia
| |
Collapse
|
4
|
Duvnjak M, Stojsavljević S, Jukić LV, Duvnjak LS. Risk Factors for Colorectal Adenoma - Acknowledging the Burden of NAFLD. J Clin Transl Hepatol 2019; 7:97-98. [PMID: 31293907 PMCID: PMC6609849 DOI: 10.14218/jcth.2019.00022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 06/25/2019] [Indexed: 12/27/2022] Open
Affiliation(s)
- Marko Duvnjak
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Sanja Stojsavljević
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
| | - Lucija Virović Jukić
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
| | - Lea Smirčić Duvnjak
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Merkur University Hospital, Zagreb, Croatia
| |
Collapse
|
5
|
Sabadi D, Peric L, Rubil I, Lisnjic D, Duvnjak M, Simasek D, Grubisic B, Radocaj V, Baraban V, Savic V, Tabain I, Barbic L, Kaic B, Stevanovic V, Vilibic-Cavlek T. Acute anteroseptal ST-Elevation Myocardial Infarction (STEMI) in the West Nile virus infection. Int J Infect Dis 2019. [DOI: 10.1016/j.ijid.2018.11.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
6
|
Unić A, Derek L, Duvnjak M, Patrlj L, Rakić M, Kujundžić M, Renjić V, Štoković N, Dinjar P, Jukic A, Grgurević I. Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis. Ann Clin Biochem 2017; 55:355-362. [DOI: 10.1177/0004563217726808] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Introduction Despite some new treatment possibilities, the improvement in survival rate for hepatocellular carcinoma (HCC) patients is still poor due to late diagnosis. The aim of this study was to investigate the diagnostic sensitivity and specificity of protein induced by vitamin K absence or antagonist-II (PIVKAII), Glypican-3 (GP3), Cystatin B (CSTB), squamous cell carcinoma antigen 1 (SCCA1) and hepatocyte growth factor (HGF) as potential tumour markers for HCC in patients with alcoholic liver cirrhosis (ALC) using imaging techniques (MSCT and MRI) as reference standards. Patients and methods Eighty-three participants were included: 20 healthy volunteers, 31 patients with ALC and 32 patients with HCC. Peripheral blood sampling was performed for each participant, and serum concentrations of PIVKAII, GP3, CSTB, SCCA1 and HGF were determined using commercial ELISA kits. Results Only serum concentrations of PIVKAII were significantly higher in HCC patients as compared with ALC and healthy controls (cut-off: 2.06 µg/L; AUC: 0.903), whereas individual diagnostic performance of other individual compounds was inadequate. The ‘best’ combination of tumour markers in our study includes all tested markers with AUC of 0.967. Conclusion While novel diagnostic tumour markers are urgently needed, the examined potential tumour markers, with the exception of PIVKAII seem to be inadequate for diagnosing HCC in ALC. Furthermore, probably the future is in finding the best optimal combination of tumour markers for diagnosing HCC based on cost-effectiveness.
Collapse
Affiliation(s)
- Adriana Unić
- University Department of Chemistry, Medical School University Hospital Sestre Milosrdnice, Zagreb, Croatia
| | - Lovorka Derek
- University Department of Chemistry, Medical School University Hospital Sestre Milosrdnice, Zagreb, Croatia
| | - Marko Duvnjak
- Division of Gastroenterology and Hepatology, Department of Medicine, Sestre Milosrdnice University Hospital, Zagreb, Croatia
- School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Leonardo Patrlj
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Surgery, University Hospital Dubrava, Zagreb, Croatia
| | - Mislav Rakić
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Surgery, University Hospital Dubrava, Zagreb, Croatia
| | - Milan Kujundžić
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - Vesna Renjić
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
| | | | - Petra Dinjar
- Department of Gastroenterology and Hepatology, University Hospital Merkur, Zagreb, Croatia
| | - Anita Jukic
- Department of Internal Medicine, University Hospital Centre Split, Split, Croatia
| | - Ivica Grgurević
- School of Medicine, University of Zagreb, Zagreb, Croatia
- Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
7
|
Bišćanin A, Ljubičić N, Boban M, Baličević D, Pavić I, Bišćanin MM, Budimir I, Dorosulic Z, Duvnjak M. CX43 Expression in Colonic Adenomas and Surrounding Mucosa Is a Marker of Malignant Potential. Anticancer Res 2017; 36:5437-5442. [PMID: 27798912 DOI: 10.21873/anticanres.11122] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Accepted: 09/02/2016] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Colorectal cancer is a major public health problem. The adenoma-carcinoma sequence offers potential for screening and surveillance. We tested the clinical behavior and diagnostic utility of connexin 43 (CX43) in connection with pathohistological risk. PATIENTS AND METHODS Immunohistochemical expression of CX43 in colonic adenomas and surrounding mucosa from 87 patients was determined. RESULTS CX43 expression was higher in mucosa surrounding adenomas with high-grade dysplasia (p=0.047), larger adenomas (p=0.015) and villous adenomas (p=0.02). No difference of CX43 expression in adenomas according to grade of dysplasia was found (p=0.87). CX43 expression in adenomas was dependent on the patient's hemoglobin level (p=0.002), family history of colorectal cancer (p=0.009) and statin therapy (p=0.049). CONCLUSION CX43 expression in mucosa surrounding adenoma could be an additional factor indicative of malignant potential. CX43 expression in colonic adenoma seems to be closely related to family history of colorectal cancer, statin therapy and hemoglobin level.
Collapse
Affiliation(s)
- Alen Bišćanin
- Division of Gastroenterology, Department of Internal Medicine, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - Neven Ljubičić
- Division of Gastroenterology, Department of Internal Medicine, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - Marko Boban
- Department of Cardiology, University Hospital Thalassotherapia Opatija, Medical Faculty University of Rijeka, Opatija, Croatia.,Department of Internal Medicine, University Hospital Osijek, Medical Faculty JJ Strossmayer University of Osijek, Osijek, Croatia
| | - Drinko Baličević
- Ljudevit Jurak University Department of Pathology, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - Ivana Pavić
- Ljudevit Jurak University Department of Pathology, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | | | - Ivan Budimir
- Division of Gastroenterology, Department of Internal Medicine, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - Zdravko Dorosulic
- Division of Gastroenterology, Department of Internal Medicine, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - Marko Duvnjak
- Division of Gastroenterology, Department of Internal Medicine, University Hospital Centre Sestre Milosrdnice, University of Zagreb School of Medicine and University of Zagreb School of Dental Medicine, Zagreb, Croatia
| |
Collapse
|
8
|
Duvnjak M, Kljak K, Grbeša D. Effect of hybrid, inoculant and storage time on whole plant nitrogen compounds and grain total zein content in maize silage. J Anim Feed Sci 2016. [DOI: 10.22358/jafs/65578/2016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Kralj D, Jukić LV, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016; 4:66-75. [PMID: 27047774 PMCID: PMC4807145 DOI: 10.14218/jcth.2015.00051] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Revised: 02/15/2016] [Accepted: 02/16/2016] [Indexed: 12/15/2022] Open
Abstract
Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide. Liver steatosis is a common finding in many hepatic and extrahepatic disorders, the most common being metabolic syndrome (MS). Over time, it has been shown that the frequent coexistence of these two conditions is not coincidental, since many epidemiological, clinical, and experimental studies have indicated HCV to be strongly associated with liver steatosis and numerous metabolic derangements. Here, we present an overview of publications that provide clinical evidence of the metabolic effects of HCV and summarize the available data on the pathogenetic mechanisms of this association. It has been shown that HCV infection can induce insulin resistance (IR) in the liver and peripheral tissues through multiple mechanisms. Substantial research has suggested that HCV interferes with insulin signaling both directly and indirectly, inducing the production of several proinflammatory cytokines. HCV replication, assembly, and release from hepatocytes require close interactions with lipid droplets and host lipoproteins. This modulation of lipid metabolism in host cells can induce hepatic steatosis, which is more pronounced in patients with HCV genotype 3. The risk of steatosis depends on several viral factors (including genotype, viral load, and gene mutations) and host features (visceral obesity, type 2 diabetes mellitus, genetic predisposition, medication use, and alcohol consumption). HCV-related IR and steatosis have been shown to have a remarkable clinical impact on the prognosis of HCV infection and quality of life, due to their association with resistance to antiviral therapy, progression of hepatic fibrosis, and development of hepatocellular carcinoma. Finally, HCV-induced IR, oxidative stress, and changes in lipid and iron metabolism lead to glucose intolerance, arterial hypertension, hyperuricemia, and atherosclerosis, resulting in increased cardiovascular mortality.
Collapse
Affiliation(s)
- Dominik Kralj
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
| | - Lucija Virović Jukić
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
- Correspondence to: Lucija Virović Jukić, Department of Gastroenterology and Hepatology, Sestre milosrdnice University Hospital Center, Vinogradska cesta 29, 10000 Zagreb, Croatia. Tel: +385-1-3787-178, Fax: +385-1-3769-067, E-mail:
| | - Sanja Stojsavljević
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
| | - Marko Duvnjak
- Department of Gastroenterology and Hepatology, Sisters of Charity University Hospital Center, Zagreb, Croatia
| | - Martina Smolić
- Department of Pharmacology, Faculty of Medicine, University of Osijek, Osijek, Croatia
| | - Ines Bilić Čurčić
- Department of Pharmacology, Faculty of Medicine, University of Osijek, Department of Endocrinology and metabolism disorders, University Hospital Center, Osijek, Osijek, Croatia
| |
Collapse
|
10
|
|
11
|
Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20:18070-18091. [PMID: 25561778 PMCID: PMC4277948 DOI: 10.3748/wjg.v20.i48.18070] [Citation(s) in RCA: 214] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Revised: 10/22/2014] [Accepted: 11/19/2014] [Indexed: 02/06/2023] Open
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of a patient with no history of alcohol abuse or other causes for secondary hepatic steatosis. The pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) has not been fully elucidated. The “two-hit“ hypothesis is probably a too simplified model to elaborate complex pathogenetic events occurring in patients with NASH. It should be better regarded as a multiple step process, with accumulation of liver fat being the first step, followed by the development of necroinflammation and fibrosis. Adipose tissue, which has emerged as an endocrine organ with a key role in energy homeostasis, is responsive to both central and peripheral metabolic signals and is itself capable of secreting a number of proteins. These adipocyte-specific or enriched proteins, termed adipokines, have been shown to have a variety of local, peripheral, and central effects. In the current review, we explore the role of adipocytokines and proinflammatory cytokines in the pathogenesis of NAFLD. We particularly focus on adiponectin, leptin and ghrelin, with a brief mention of resistin, visfatin and retinol-binding protein 4 among adipokines, and tumor necrosis factor-α, interleukin (IL)-6, IL-1, and briefly IL-18 among proinflammatory cytokines. We update their role in NAFLD, as elucidated in experimental models and clinical practice.
Collapse
|
12
|
Pavic T, LJubicic N, Marout J, Milosevic M, Budimir I, Biscanin A, Duvnjak M. PP063-SUN: Hormonal Dysfunction in Patients with Biliary Obstruction. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50105-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
Hugle B, Burgos-Vargas R, Inman RD, O'Shea F, Laxer RM, Stimec J, Whitney-Mahoney K, Duvnjak M, Anderson M, Tse SML. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 2014; 32:424-431. [PMID: 24387974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 11/06/2013] [Indexed: 06/03/2023]
Abstract
OBJECTIVES A significant proportion of patients with juvenile spondyloarthritis (JSpA) are refractory to treatment with established medications. The objective of this study was to assess long-term efficacy of treatment with anti-TNF agents in patients with JSpA. METHODS An observational study of 16 patients with JSpA from 3 centres treated with infliximab (n=10) and etanercept (n=6) was performed, with a median follow-up period of 7.2 years. Prospective data was collected according to a standardized protocol. Outcomes examined were TEC, TAJC, markers of inflammation (ESR, CRP), functional assessments (C-HAQ, BASDAI, BASFI), and ongoing requirement for anti-TNF treatment. RESULTS 13/16 patients (83%) had achieved clinical remission 6 months into the treatment. Improvement was sustained over time, with a median TAJC and TEC of 0 at any time point after 6 weeks. 6/16 patients (38%) showed a flare of arthritis after a median of 3.5 years. Two patients with hip disease prior to treatment required an arthroplasty 3 and 8 years post anti-TNF initiation. Patients showed progression of sacroiliitis with median modified New York score of 1 (range 0-3) at time of diagnosis and 3 (range 0-4) at last follow-up (p=0.002). Median BASDAI at last follow up was 1.6, median BASFI 3.1. Two patients developed transient reactions (one generalised, one local); no patient developed other adverse effects during the study. CONCLUSIONS Anti-TNF treatment in JSpA refractory to standard treatment results in good long-term disease control except for pre-existing hip disease. However, radiographic evidence suggests inferior efficacy for control of sacroiliac joint disease.
Collapse
Affiliation(s)
- B Hugle
- Division of Rheumatology, The Hospital for Sick Children, University of Toronto, Canada, and German Center for Paediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Budimir I, Nikolić M, Pusić MS, Hrabar D, Ljubicić N, Duvnjak M, Supanc V, Nikolac I, Babić N, Sokcević M. Waldenström's macroglobulinemia as a diagnostic challenge: case report. Acta Clin Croat 2014; 53:94-97. [PMID: 24974671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023] Open
Abstract
Waldenström's macroglobulinemia is a distinct clinicopathologic entity defined as a B-cell neoplasm characterized by lymphoplasmacytic infiltrate in the bone marrow, with an associated immunoglobulin (Ig) M paraprotein. Clinical manifestations are due to deposition of IgM in the liver, spleen, and/or lymph nodes, so it presents with anemia, hyperviscosity, lymphadenopathy, hepatomegaly, splenomegaly and neurologic symptoms. The main diagnostic criteria are a typical peak on serum protein electrophoresis and malignant cells in bone marrow biopsy samples. There is no standard therapy for the treatment of symptomatic Waldenstrom's macroglobulinemia and no agents have been specifically approved for this disease, but initial treatment usually starts with the monoclonal anti-CD20 antibody rituximab, either alone or in combination with other agents, rather than chemotherapy alone. This article confirms that, despite the existence of more modern imaging methods, ultrasonography still has a significant diagnostic role.
Collapse
|
15
|
Bulum T, Kolarić B, Duvnjak M, Duvnjak L. Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients. Ren Fail 2014; 36:372-7. [PMID: 24455970 DOI: 10.3109/0886022x.2013.872569] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of chronic kidney disease in patients with type 1 diabetes. The aim of this study was to explore the relationship between markers of NAFLD, namely concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-glutamyltransferase (GGT), bilirubin, and renal function in type 1 diabetic patients. This study included 313 normoalbuminuric type 1 diabetic patients with estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m(2), without clinical evidence of cirrhosis or other causes of chronic liver disease and before any interventions with statins, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers. ALT, GGT, and bilirubin levels were significantly higher in subjects in the highest quartile of serum creatinine compared to those in lowest quartile (21 vs. 20 U/L, 18 vs. 14 U/L, and 14 vs. 10 µmol/L, respectively, for all p < 0.05). ALK levels were significantly higher in subjects in the highest quartile of urinary albumin excretion rate compared to those in lowest quartile (71 vs. 69 U/L, p = 0.03), as well as in hyperfiltrating subjects compared to those with normal or mildly impaired eGFR (81 vs. 68 and 64 U/L, p < 0.001). In a multiple logistic regression model adjusted for age, sex, duration of diabetes, HbA1c, and body mass index (BMI), only ALK levels were significantly associated with disturbances in serum creatinine and eGFR in our subjects (p ≤ 0.007), with odds ratios of 0.98-1.02. NAFLD associated markers, particularly ALK, are associated with renal function in normoalbuminuric type 1 diabetic patients.
Collapse
Affiliation(s)
- Tomislav Bulum
- Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur , Zagreb , Croatia
| | | | | | | |
Collapse
|
16
|
Katicić M, Duvnjak M, Kanizaj TF, Krznarić Z, Marusić M, Mihaljević S, Plecko V, Pulanić R, Simunić M, Tonkić A. [Croatian guidelines for diagnostics and treatments of Helicobacter pylori infection]. Lijec Vjesn 2014; 136:1-17. [PMID: 24720149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In the past 30-year period of investigations, the crucial role of Helicobacter pylori in chronic gastritis, gastric and duodenal ulcer development, and subsequently in gastric cancer and MALT lymphoma pathogenesis, has been recognized. During the first meeting of European Helicobacter Study Group in 1996 in Maastricht, the first recommendations for diagnostics and treatments of Helicobacter pylori infection were published, later reviewed in 2000, 2007 and 2010. The first meeting of Croatian doctors focusing on the same topics, but suitable to specific national circumstances, was held as early as 1998. The need for updating the old guidelines has emerged during the last years. The working expert group of gastroenterologists was formed and gathered on Consesus Conference in December 2012 in Zagreb, to arrive to current guidelines for the clinical management of Helicobacter pylori infection in Croatia. The following topics relating to Helicobacter pylori infection were examined: 1. indications and contraindications for diagnostics and treatments; 2. diagnostic methods and 3. treatments applicable in our country.
Collapse
|
17
|
Vince A, Duvnjak M, Kurelac I. [Treatment guidelines for patients with genotype 1 chronic hepatitis C infection]. Acta Med Croatica 2013; 67:329-338. [PMID: 24984333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Dual therapy based on the combination of pegylated interferon-alpha 2a or 2b (PEG IFN-alpha2) and ribavirin has been considered standard-of-care treatment for chronic hepatitis C genotype 1 up to 2011. The first generation of protease inhibitors, boceprevir and telaprevir, have been approved for clinical use in Europe and USA since 2011. Therefore, national guidelines for the treatment of chronic hepatitis C genotype 1 have been updated to include new and more efficient therapeutic options. Croatian guidelines are based on the results of registration clinical trials for boceprevir and telaprevir, national guidelines of several EU countries (United Kingdom, Sweden, Germany, France and Italy), EASL and AASLD recommendations, as well as on the results of chronic hepatitis C genotype 1 treatment with dual therapy at the national level. The Croatian guidelines include recommendations for treatment-naïve and treatment-experienced patients (based on the type of virologic response to the first-line treatment). In treatment-naïve patients with mild fibrosis and favorable predictors of treatment outcome, dual therapy is the recommended treatment option. In treatment-naïve patients with advanced fibrosis (F3 and F4) as well as in patients with moderate fibrosis (F2) and unfavorable predictors of treatment outcome (age > 40 years, non-CC IL-28B genotype, non-RVR), triple therapy is recommended. Triple therapy is also recommended for relapsers (irrespective of fibrosis stage) and partial responders with advanced fibrosis (F3 and F4). Lead-in treatment strategy during triple therapy is recommended for null-responders.
Collapse
|
18
|
Vince A, Hrstić I, Begovac J, Bradarić N, Colić-Cvrlje V, Duvnjak M, Rode OD, Kanizaj TF, Grgurević I, Kekez AJ, Kaić B, Kes P, Kurelac I, Milić S, Morović M, Mrzljak A, Ostojić R, Poljak M, Slavicek J, Smolić M, Stimac D, Vcev A, Vucelić B, Lepej SZ. [Viralhepatitis. Croatian Consensus Statement 2013]. Acta Med Croatica 2013; 67:263-72. [PMID: 24984325 DOI: pmid/24984325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Croatian Consensus Conferences on Viral Hepatitis took place in 2005 and 2009. Considering the numerous novel concepts on the epidemiology, diagnosis and management of viral hepatitis (chronic hepatitis C genotype 1 in particular) that have emerged in the past four years, a new Croatian Consensus Conference on Viral Hepatitis was held in Zagreb on February 28, 2013. The abridged text of the Croatian Consensus Conference on Viral Hepatitis 2013 presents the new concepts on the epidemiology of viral hepatitis, serologic and molecular diagnosis of viral hepatitis, determination of the IL-28 gene promoter polymorphism, fibrosis grading, algorithm for patient diagnostic follow up, treatment of chronic hepatitis C (genotypes 1-6) and hepatitis B, treatment of special populations (children, dialysis patients, transplanted patients, individuals with HIV/HCV co-infection), and therapy side effects.
Collapse
MESH Headings
- Adolescent
- Adult
- Age Factors
- Aged
- Child
- Croatia/epidemiology
- Delivery of Health Care/organization & administration
- Genotype
- Hepacivirus/genetics
- Hepacivirus/isolation & purification
- Hepatitis B, Chronic/diagnosis
- Hepatitis B, Chronic/drug therapy
- Hepatitis C, Chronic/diagnosis
- Hepatitis C, Chronic/drug therapy
- Hepatitis, Viral, Human/diagnosis
- Hepatitis, Viral, Human/drug therapy
- Hepatitis, Viral, Human/epidemiology
- Hepatitis, Viral, Human/genetics
- Humans
- Middle Aged
- Risk Factors
- Young Adult
Collapse
|
19
|
Vucelić B, Cuković-Cavka S, Banić M, Bilić A, Borzan V, Duvnjak M, Katicić M, Kolacek S, Krznarić Z, Kujundzić M, Marusić M, Mihaljević S, Mijandrusić BS, Persić M, Simunić M, Skurla B, Stimac D, Tonkić A, Troskot B. [Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy]. Acta Med Croatica 2013; 67:75-87. [PMID: 24471291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Introduction of biologic therapy in clinical practice represented significant progress in the treatment of inflammatory bowel diseases (IBD) because of its proven efficacy and due to the fact that biologics are the first drugs used in the treatment of IBD that can change the natural course of this diseases. At the same time, biologics are very expensive drugs with complex mechanism of action and important side effects and their use requires evidence-based clinical guidelines. These were the reasons that Referral Center of the Croatian Ministry of Health for IBD and the IBD Section of the Croatian Society of Gastroenterology organised Croatian consensus conference that defined guidelines for the treatment of IBD with anti-TNF drugs. The text below includes definitions of IBD, general principles of IBD therapy, comments on the importance of mucosal healing, analysis of reasons for nonresponse and loss of response to anti-TNF drugs, recommendation for the duration of anti-TNF therapy, rules of screening for opportunistic infections prior to anti-TNF therapy, comments on the problems with reproduction in IBD and finally guidelines for the treatment of various phenotypes of IBD including extraintestinal manifestations with anti-TNF therapy.
Collapse
Affiliation(s)
- Boris Vucelić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska.
| | - Silvija Cuković-Cavka
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Marko Banić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Ante Bilić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Vladimir Borzan
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Marko Duvnjak
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Miroslava Katicić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Sanja Kolacek
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Zeljko Krznarić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Milan Kujundzić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Marinko Marusić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Silvio Mihaljević
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Brankica Sincić Mijandrusić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Mladen Persić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Miroslav Simunić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Bruno Skurla
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Davor Stimac
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Ante Tonkić
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| | - Branko Troskot
- Referentni centar Ministarstva zdravlja Republike Hrvatske za kroniZne upalne bolesti crijeva, Sekcija za upalne bolesti crijeva, Hrvatsko gastroenterolosko drustvo, Zagreb, Hrvatska
| |
Collapse
|
20
|
Duvnjak M, Bilić A, Barsić N, Tomasić V, Stojsavljević S. [Classical medications in the treatment of inflammatory bowel diseases]. Acta Med Croatica 2013; 67:111-124. [PMID: 24471294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The treatment of inflammatory bowel diseases is complex and requires individual approach to every single patient. Traditionally, the approach is based on introduction of so called "classical" medication into the treatment regimen, from ones less potent and with fewer side effects to the ones more toxic but also therapeutically more effective. Aminosalicylates were the first choice of treatment for a long time. However, the role of aminosalicylates is becoming more and more diminished, although they are still the drug of choice in the treatment of mild to moderate ulcerative colitis. Corticosteroids are the therapy of choice in treatment of active IBD for achieving remission in moderate to severe disease. Azathioprine and 6- mercaptopurine belong to a group of thiopurines with an immunomodulatory effect which, in Crohn's disease as well as in ulcerative colitis, primarily have a role in a steroid dependant or steroid refractory type of disease and in maintenance of remission. Lately, early introduction of these medications is proposed to enhance the number of patients that remain in remission. Methotrexate is used for the therapy of active and relapsing Crohn's disease and represents an alternative in patients who do not tolerate or do not respond to azathioprine or 6-mercaptopurine therapy. Cyclosporine is used in treating steroid refractory ulcerative colitis and in some patients can postpone the need for colectomy. Antibiotics do not have a proven effect on the course of inflammatory bowel diseases and their primary role is to treat septic complications. Classic medications today represent a standard in the management of inflammatory bowel diseases, and the combination of the previously mentioned drugs often has a more potent effect on the course of the disease than any medication on its own and their combination is still an object of investigations and clinical studies.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Hrvatska.
| | - Ante Bilić
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica Sveti Duh, Zagreb, Hrvatska
| | - Neven Barsić
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Hrvatska
| | - Vedran Tomasić
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Hrvatska
| | - Sanja Stojsavljević
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Hrvatska
| |
Collapse
|
21
|
Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18:3945-54. [PMID: 22912545 PMCID: PMC3419991 DOI: 10.3748/wjg.v18.i30.3945] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 03/01/2012] [Accepted: 03/09/2012] [Indexed: 02/06/2023] Open
Abstract
High prevalence of non-alcoholic fatty liver disease (NAFLD) and very diverse outcomes that are related to disease form and severity at presentation have made the search for noninvasive diagnostic tools in NAFLD one of the areas with most intense development in hepatology today. Various methods have been investigated in the recent years, including imaging methods like ultrasound and magnetic resonance imaging, different forms of liver stiffness measurement, various biomarkers of necroinflammatory processes (acute phase reactants, cytokines, markers of apoptosis), hyaluronic acid and other biomarkers of liver fibrosis. Multicomponent tests, scoring systems and diagnostic panels were also developed with the purposes of differentiating non-alcoholic steatohepatitis from simple steatosis or discriminating between various fibrosis stages. In all of the cases, performance of noninvasive methods was compared with liver biopsy, which is still considered to be a gold standard in diagnosis, but is by itself far from a perfect comparative measure. We present here the overview of the published data on various noninvasive diagnostic tools, some of which appear to be very promising, and we address as well some of still unresolved issues in this interesting field.
Collapse
|
22
|
Bulum T, Kolarić B, Duvnjak L, Duvnjak M. Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 2011; 56:3655-63. [PMID: 21735081 DOI: 10.1007/s10620-011-1807-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Accepted: 06/15/2011] [Indexed: 02/06/2023]
Abstract
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin resistance. AIMS To explore the relationship between markers of NAFLD, namely concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-glutamyltransferase (GGT), ferritin and bilirubin and insulin resistance in type 1 diabetes. METHODS Our study included 353 patients with type 1 diabetes. Insulin sensitivity was measured with estimated glucose disposal rate calculated using the equation: eGDR = 24.31 - (12.22 × WHR) - (3.29 × HT) - (0.57 × HbA1c); WHR = waist to hip ratio, HT = hypertension. Correlations and multiple logistic regressions analysis were performed to identify the relationships between NAFLD associated markers and eGDR, individual components of insulin resistance and risk of insulin resistance. RESULTS AST, ALT, AST-to-ALT ratio, ALK and ferritin significantly correlated with insulin resistance measured by eGDR (r = -0.13, -0.14, 0.13, -0.18, and -0.24, respectively; all P < 0.05), and with individual components of insulin resistance, most notably WHR. In a multiple logistic regression model adjusted according to age, sex, duration of diabetes and BMI, increased levels of AST, ALT and ALK resulted in an increased risk for the development of insulin resistance in our subjects (OR = 1.03, 1.02, and 1.01, respectively; all P < 0.05). CONCLUSIONS These findings indicate that higher levels of ALT, AST and ALK are additional markers of insulin resistance in type 1 diabetes and suggest that those subjects must be considered as potentially affected not only by a hepatic but also by a multisystemic disease through altered insulin sensitivity.
Collapse
Affiliation(s)
- Tomislav Bulum
- Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zajčeva 19, 10000 Zagreb, Croatia.
| | | | | | | |
Collapse
|
23
|
Abstract
Acid secretion from gastric parietal cells is a result of a complex interaction between different stimulatory and inhibitory mediators. One of the most important mediators is gastrin, which stimulates gastric acid secretion from parietal cells mostly indirectly, by the release of histamine from enterochromaffin-like (ECL) cells. Therapy with antisecretory agents leads to hypergastrinemia, mucosal hyperplasia and increased ECL cell mass, which results in increase of gastric acid secretion capacity. This increased secretion capacity has been shown to manifest itself after antisecretory therapy withdrawal as rebound acid hypersecretion (RAH). Various studies have quantified acid hypersecretion after the cessation of therapy with H(2) antagonists and proton-pump inhibitors (PPIs). While most of those studies had small patient numbers, the findings generally demonstrate that RAH after H(2) antagonist therapy is of low magnitude, short duration, and has questionable clinical significance. On the contrary, acid hypersecretion after PPI therapy is more pronounced, lasts longer, and could possibly be the cause of acid-related symptoms. Potential for causing symptoms has recently been confirmed in two randomized placebo-controlled studies, and while we witness the increasing use of PPIs, RAH could become a proven cause of failure to withdraw therapy in a proportion of patients with reflux or dyspeptic symptoms.
Collapse
Affiliation(s)
- Ivan Lerotić
- Department of Gastroenterology and Hepatology, Sestre milosrdnice University Hospital, Zagreb, Croatia
| | | | | | | |
Collapse
|
24
|
Pavić T, Hrabar D, Duvnjak M. The role of endoscopic ultrasound in evaluation of gastric subepithelial lesions. Coll Antropol 2010; 34:757-762. [PMID: 20698167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
A subepithelial mass is a common finding during endoscopic procedures. Endoscopic ultrasound (EUS) is an important diagnostic modality in the evaluation of subepithelial lesions of the gastrointestinal tract. EUS is the diagnostic test of choice to assess the size, margins, the layer of origin, echotexture, and to differentiate between an intramural and extramural lesion. However, the EUS imaging lacks the specificity. EUS-guided fine needle aspiration (EUS-FNA) or core biopsy can help establish a tissue diagnosis and potentially characterize malignant risk. The aim of this article is to review the diagnosis and management of the most common subepithelial gastric lesions with an emphasis on the role of endoscopic ultrasound.
Collapse
Affiliation(s)
- Tajana Pavić
- Department of Gastroenterology and Hepatology, "Sestre Milosrdnice" University Hospital, Zagreb, Croatia.
| | | | | |
Collapse
|
25
|
Duvnjak M, Baršić N, Tomašić V, Lerotić I. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression. World J Gastroenterol 2009; 15:6023-7. [PMID: 20027673 PMCID: PMC2797657 DOI: 10.3748/wjg.15.6023] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis through steatohepatitis to advanced fibrosis and cirrhosis. Although the reason why only a minority of patients develop progressive forms of disease still remains largely unclear, recent research has identified genetic factors as a possible basis for this variation in disease presentation. Most of the studies have been focused on finding associations between advanced disease forms and selected single nucleotide polymorphisms in genes encoding various proteins involved in disease pathogenesis. Although there are many limitations regarding the study design and interpretation of published data, further carefully planned studies together with implementation of new genetic technologies will likely bring new insights into disease pathogenesis and potential benefits to the management of patients with NAFLD.
Collapse
|
26
|
Hrabar D, Gomercić M, Duvnjak M, Ljubicić N, Pavić T, Nikolić M. [Endoscopic ultrasonography in the diagnosis of choledocholithiasis]. Acta Med Croatica 2009; 63 Suppl 3:5-9. [PMID: 20232666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND Endoscopic retrograde cholangiopancreatography (ERCP) has been considered a gold standard in the diagnosis of choledocholithiasis; however, the incidence of complications is high. In literature reports, the morbidity rate ranges from 5% to 19% and mortality rate from 0.1% to 1.3%, therefore an effective but less invasive new method of diagnosing choledocholithiasis is required. In a number of trials, endoscopic ultrasonography (EUS) has been shown to be a less invasive method with excellent sensitivity of 94% and specificity of 95%. The aim of this study was to estimate the sensitivity and specificity of EUS in patients with suspected choledocholithiasis and to establish its role in the algorithm for diagnosing choledocholithiasis. PATIENTS AND METHODS Patient files were retrospectively reviewed in 209 patients with a clinical picture and ultrasonography findings suggestive of choledocholithiasis, admitted to Sestre milosrdnice University Hospital during a six-month period (Sep 1, 2007 - Feb 29, 2008) and submitted to ERCP within 72 hours of admission. RESULTS In 125 patients with abdominal ultrasonography findings suggestive of choledocholithiasis (biliary obstruction without clear evidence of calculi), EUS was performed before ERCR. Choledocholithiasis or biliary sludge was identified in 66 (62.3%) patients, 29 (27.3%) patients were free from biliary abnormalities, and 11 (10.4%) patients had stenosis of different etiology. In 64 of 66 (96.9%) patients, the diagnosis was confirmed by ERCP. Another two (3.1%) patients had no evidence of choledocholithiasis on ERCP. There were no complications related to EUS. CONCLUSIONS EUS is an effective method for diagnosing choledocholithiasis with a sensitivity and specificity comparable to ERCP. Therefore, it is reasonable to use EUS as the first method of choice in patients with suspected choledocholithiasis.
Collapse
Affiliation(s)
- Davor Hrabar
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska.
| | | | | | | | | | | |
Collapse
|
27
|
Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009; 60 Suppl 7:19-24. [PMID: 20388942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/15/2009] [Accepted: 12/11/2009] [Indexed: 05/29/2023]
Abstract
The metabolic syndrome refers to the clustering of cardiovascular risk factors that include diabetes, obesity, dyslipidaemia and hypertension. Due to various definitions and unexplained pathophysiology it is still a source of medical controversy. Insulin resistance and visceral obesity have been recognized as the most important pathogenic factors. Insulin resistance could be defined as the inability of insulin to produce its numerous actions, in spite of the unimpaired secretion from the beta cells. Metabolic abnormalities result from the interaction between the effects of insulin resistance located primarily in the muscle and adipose tissue and the adverse impact of the compensatory hyperinsulinaemia on tissues that remain normally insulin-sensitive. The clinical heterogeneity of the syndrome can be explained by its significant impact on glucose, fat and protein metabolism, cellular growth and differentiation, and endothelial function. Visceral fat represents a metabolically active organ, strongly related to insulin sensitivity. Moderating the secretion of adipocytokines like leptin, adiponectin, plasminogen activator inhibitor 1 (PAI-1), tumor necrosis factor alfa (TNF-alfa), interleukin-6 (IL-6) and resistin, it is associated with the processes of inflammation, endothelial dysfunction, hypertension and atherogenesis. In 2005, the International Diabetes Federation (IDF) has proposed a new definition, based on clinical criteria and designed for global application in clinical practice. Visceral obesity measured by waist circumference is an essential requirement for diagnosis; other variables include increased triglyceride and decreased HDL levels, hypertension and glucose impairment. Whatever the uncertainties of definition and etiology, metabolic syndrome represents a useful and simple clinical concept which allows earlier detection of type 2 diabetes and cardiovascular disease.
Collapse
Affiliation(s)
- L Duvnjak
- Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Zagreb, Croatia.
| | | |
Collapse
|
28
|
Gomercić M, Duvnjak M, Barsić N. [Ultrasonography in the diagnosis of nonalcoholic fatty liver disease]. Acta Med Croatica 2009; 63 Suppl 3:1-3. [PMID: 20235368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. Although no specific studies have been performed, the estimated prevalence of NAFLD in Croatia correlates with the prevalence in other countries, ranging from 20% to 40%. It encompasses a histological spectrum that ranges from simple steatosis to steatohepatitis, which can progress to cirrhosis in up to 20% of patients. Unfortunately, accurate noninvasive modalities for diagnosing nonalcoholic steatohepatitis (NASH) and monitoring disease progression or regression are unavailable. Therefore, liver biopsy remains the gold standard in diagnosing NASH but it is also associated with risks and possible sampling errors. Since liver biopsy cannot be performed as a screening method to detect NAFLD in general population, abdominal ultrasonography as a noninvasive modality has been widely used. Although sonographic characteristics of NAFLD were first described 20 years ago, larger studies have been conducted over the past few years as a result of the rising interest in NAFLD among investigators. The aim of these studies was to simplify the diagnosis of NASH. Abdominal ultrasonography has been shown to have a sensitivity of 60%-94% and specificity of 84%-95% for detecting fatty liver and it is used as a screening method in patients with incidental elevation of liver enzymes. Ultrasonographic scoring system developed by Hamaguchi et al. included hepatorenal echo contrast, liver brightness, deep attenuation, and vascular blurring. Score > or = 2 corresponded to NAFLD with a high, 92% sensitivity and 100% specificity, and a high level of intraobserver reliability.The inability to distinguish different forms of NAFLD and staging hepatic fibrosis limits the use of ultrasonography as a stand alone modality for detecting NAFLD. In the future, serum markers together with advancements in imaging modalities may potentially diminish or obviate the need of liver biopsy.
Collapse
Affiliation(s)
- Marija Gomercić
- Zavod za gastroenterologiju i hepatologiju, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska
| | | | | |
Collapse
|
29
|
Pavić T, Hrabar D, Duvnjak M, Ljubicić N, Tomasić V, Nikolić M. [The role of endoscopic ultrasonography in the evaluation of pancreatic cancer]. Acta Med Croatica 2009; 63 Suppl 3:39-42. [PMID: 20232669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Pancreatic cancer has a dismal prognosis and complete surgical removal remains the only potential curative treatment. The principle goal of preoperative evaluation is to identify patients with potentially resectable disease while avoiding surgical exploration in those with unresectable disease. There is no evidence-based consensus on the optimal preoperative imaging assessment of patients with suspected pancreatic cancer. Because of its widespread availability, computed tomography (CT) is usually the initial study for this indication, although endoscopic ultrasonography (EUS) is the most sensitive imaging modality for the detection of pancreatic masses. Due to anatomical limitations, CT and magnetic resonance (MR) are superior to EUS for detection of metastatic disease. EUS is superior to CT and angiography for detection of tumor invasion of the portal vein or confluence. Most studies found no significant differences between EUS, CT and MRI in determination of pancreatic cancer resectability. The optimal place of EUS within the diagnostic algorithm remains dependent on local referral modalities and availability.
Collapse
Affiliation(s)
- Tajana Pavić
- Zavod za gastroenterologiju i hepatologliju, Klinika za unutarnje bolesti, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska
| | | | | | | | | | | |
Collapse
|
30
|
Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N, Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009; 60 Suppl 7:57-66. [PMID: 20388946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/15/2009] [Accepted: 12/20/2009] [Indexed: 05/29/2023]
Abstract
Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, has become a common entity in clinical practice. In most of the patients it presents as simple steatosis with nonprogressive clinical course. However, some patients have progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), and are at increased risk of developing cirrhosis and hepatocellular carcinoma. NAFLD treatment includes lifestyle modifications and pharmacotherapy aiming at increasing insulin sensitivity, and attenuating inflammation and hepatic fibrosis. Weight reduction has consistently been shown to reduce levels of liver enzymes and insulin resistance. Although dietary intervention and exercise remain the first-line therapy, due to low patients compliance to these measures pharmacotherapy or surgical approaches are often required. Metformin and thiazolidinediones may improve insulin sensitivity, serum aminotransferase level and liver histology. However, little evidence exists regarding their sustained effects after drug discontinuation which, together with their side effects, limits their widespread use in clinical practice. Statins appear to be safe agents for the treatment of hyperlipidemia, although trials documenting their efficacy in NAFLD are scarce. Based on the recent clinical trials, weight loss medication orlistat, ursodeoxycholic acid and antioxidant agents could potentially be used as adjunctive therapy. Considering still largely controversial clinical data regarding pharmacological agents, their high cost and known side-effects, lifestyle modifications at present remain the only essential considerations in the NAFLD treatment.
Collapse
Affiliation(s)
- M Duvnjak
- Division of Gastroenterology and Hepatology, Department of Medicine Sestre Milosrdnice University Hospital, Zagreb, Croatia.
| | | | | | | | | | | |
Collapse
|
31
|
Ostojić R, Vince A, Hrstić I, Zidovec Lepej S, Begovac J, Bradarić N, Burek V, Colić-Cvrlje V, Duvnjak M, Horvat J, Jaklin Kekez A, Kes P, Lesnikar V, Mikulić R, Milić S, Mise S, Morović M, Pavić I, Sakoman S, Slavicek J, Stimac D, Vcev A, Vucelić B. [Viral hepatitis. Croatian consensus conference--2009]. Acta Med Croatica 2009; 63:349-357. [PMID: 20198892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Summarized text of Croatian Consensus Conference on Viral Hepatitis of 2009 comprises the following chapters: 1) Epidemiology, 2) Clinical Picture, 3) Diagnostic Procedure, 4) Aims of Treatment of Viral Hepatitis, 5) Terminology, 6) Medicaments (6.1. Interferon, 6.2. Analogues of Nucleozides and Nucleotides), 7) Hepatitis B (7.1. Serologic and Molecular HBV Diagnostics, 7.2. Terminology, 7.3.Whom to Treat? 7.4. Therapy), 8) Hepatitis C (8.1. Serologic and Molecular HCV Diagnostics, 8.2. Terminology, 8.3. Whom to Treat? 8.4. Therapy). Clinical, laboratory and histologic assessment of patients with chronic viral hepatitis (algorythm of pretherapeutic treatment; histologic evaluation) and notions related to therapy of viral hepatitis (category of the patient and category of the response to treatment) are presented in related tables.
Collapse
|
32
|
Vince A, Duvnjak M. [Treatment of naive patients with chronic hepatitis C]. Acta Med Croatica 2009; 63:409-415. [PMID: 20198900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
According to published data, 60% of hepatitis C virus (HCV)-infected patients in Croatia have HCV genotype 1. The second most common genotype is 3a (36%). Standard treatment regimen for patients with chronic hepatitis C is a combination of pegylated interferon alfa (2a or 2b) with ribavirin, in duration guided by genotype: patients with genotype 1 are treated for 48 weeks and patients with genotypes 2 and 3 for 24 weeks in order to achieve virus elimination defined as HCV RNA undetectability 24 weeks after the treatment period (SVR). These treatment regimens fail to achieve SVR in 50% of patients with genotype 1 and 25% of patients with genotype 3. On the other hand, patients with low viral load (<600 000 IU HCV RNA/mL) and rapid viral response (RVR) could benefit from shortened treatment. Recent studies and meta-analyses have shown the importance of liver fibrosis, viral kinetics and viremia as predictors of SVR. Currently, treatment of chronic hepatitis C should be individualized (treatment guided) according to the genotype, liver fibrosis, early viral kinetics and viremia. In patients with genotype 1 who are late responders (pEVR), therapy should be prolonged to 72 weeks in order to achieve 12% better SVR. In patients with genotype 2,3 with low viremia who are rapid responders (RVR+), therapy can be shortened to 16 weeks. Patients with higher fibrosis rates (presence of fibrotic septa) should not be treated according to the level of viremia, as it has been shown that viremia does not correlate with SVR in these patients. Liver biopsy is still recommended in the pretreatment evaluation protocol for its prognostic features. In patients with acute hepatitis C, treatment should be started if HCV RNA is still present at week 12. The suggested treatment regimen is monotherapy with pegylated interferon alfa (2a or 2b) for 24 weeks.
Collapse
Affiliation(s)
- Adriana Vince
- Dr. Fran Mihaljević University Hospital, Zagreb, Croatia.
| | | |
Collapse
|
33
|
Nikolić M, Boban M, Ljubicić N, Duvnjak M, Hrabar D, Pavić T. [Evaluation of upper gastrointestinal submucosal lesions by endoscopic ultrasonography]. Acta Med Croatica 2009; 63 Suppl 3:29-37. [PMID: 20232668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Endoscopy is an established method for diagnosing gastrointestinal tract diseases, however, suspected subepithelial lesions usually cannot be appropriately evaluated by this technique alone. The prevalence of suspected submucosal gastric lesions at routine endoscopy has been estimated to 0.5%-1%. In this review, we evaluated the role of endoscopic ultrasonography (EUS) in the diagnosis of and management strategy for submucosal lesions. EUS has emerged as the most reliable investigative procedure of choice for evaluating submucosal tumors. EUS is the method of choice to differentiate between true intramural tumors and lesions caused by extraluminal compressions due to normal or pathologic structures. It can determine the originating layer(s) of intramural lesions; can differentiate echogenicity (anechoic, hypoechoic, hyperechoic, isoechoic), vascularity, size, shape, and border characteristics. Some endoscopic findings (color, consistency, mobility, 'pillow sign') can be helpful in narrowing the differential diagnosis. On the other hand, determination of the histologic layer and the internal echo patterns of some submucosal tumors are also predictive of benign or malignant tumors. EUS can provide an accurate diagnosis in 80% of patients with benign lesions and 64% of those with malignant lesions. Hypoechoic lesions in the 3rd and 4th layer are most prone to misclassification. If these cannot be differentiated exactly, EUS can serve as a guide on fine needle aspiration (FNA) biopsy or histologic core biopsies, providing samples for cytologic or histologic analysis. After that, the endoscopist can decide whether the lesion should be periodically followed up, or removed by endoscopy, endoscopic submucosal resection (EMR) or surgery.
Collapse
Affiliation(s)
- Marko Nikolić
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska.
| | | | | | | | | | | |
Collapse
|
34
|
Abstract
Nonalcoholic fatty liver disease (NAFLD) has, although it is a very common disorder, only relatively recently gained broader interest among physicians and scientists. Fatty liver has been documented in up to 10 to 15 percent of normal individuals and 70 to 80 percent of obese individuals. Although the pathophysiology of NAFLD is still subject to intensive research, several players and mechanisms have been suggested based on the substantial evidence. Excessive hepatocyte triglyceride accumulation resulting from insulin resistance is the first step in the proposed ‘two hit’ model of the pathogenesis of NAFLD. Oxidative stress resulting from mitochondrial fatty acids oxidation, NF-κB-dependent inflammatory cytokine expression and adipocytokines are all considered to be the potential factors causing second hits which lead to hepatocyte injury, inflammation and fibrosis. Although it was initially believed that NAFLD is a completely benign disorder, histologic follow-up studies have showed that fibrosis progression occurs in about a third of patients. A small number of patients with NAFLD eventually ends up with end-stage liver disease and even hepatocellular carcinoma. Although liver biopsy is currently the only way to confirm the NAFLD diagnosis and distinguish between fatty liver alone and NASH, no guidelines or firm recommendations can still be made as for when and in whom it is necessary. Increased physical activity, gradual weight reduction and in selected cases bariatric surgery remain the mainstay of NAFLD therapy. Studies with pharmacologic agents are showing promising results, but available data are still insufficient to make specific recommendations; their use therefore remains highly individual.
Collapse
Affiliation(s)
- Marko Duvnjak
- Division of Gastroenterology and Hepatology, Department of Medicine, Sestre Milosrdnice University Hospital, Vinogradska 29, Zagreb, Croatia.
| | | | | | | | | | | |
Collapse
|
35
|
Virovic Jukic L, Duvnjak M, Barsic N, Lerotic I, Tomasic V, Pavic T. Pericarditis in exacerbation of ulcerative colitis. Acta Gastroenterol Belg 2006; 69:390-2. [PMID: 17343082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Acute pericarditis occurs very rarely in association with inflammatory bowel disease (IBD). It has been described both as an extraintestinal manifestation of IBD and as an adverse drug reaction in IBD treatment. We present a case of a 26-year-old female patient with a severe exacerbation of ulcerative colitis, who was previously under long-term treatment with mesalazine and low-dose prednisone. The literature on pericardial involvement in IBD is reviewed.
Collapse
Affiliation(s)
- L Virovic Jukic
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Sestre Milosrdnice University Hospital, Zagreb, Croatia
| | | | | | | | | | | |
Collapse
|
36
|
Duvnjak M, Barsić N, Tomasić V, Virović Jukić L, Lerotić I, Pavić T. Adjusted blood requirement index as indicator of failure to control acute variceal bleeding. Croat Med J 2006; 47:398-403. [PMID: 16758517 PMCID: PMC2080432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023] Open
Abstract
AIM To estimate the clinical value of adjusted blood requirement index (ABRI) in relation to other criteria for failure of variceal bleeding control proposed at Baveno consensus workshops and to evaluate ABRI as an early predictor of occurrence of other Baveno criteria and identification of possible predictors of unfavorable ABRI. METHODS We retrospectively analyzed the data on 60 patients admitted to the hospital due to acute variceal bleeding. Number of treatment failures according to Baveno II-III and Baveno IV definitions and criteria was compared. We tested the ABRI's predictability of other Baveno IV and Baveno II-III criteria. Logistic regression analysis was performed to ascertain independent variables that predict ABRI> or =0.75. RESULTS Failure to control variceal bleeding occurred in 40 of 60 patients according to Baveno II-III criteria, and in 35 of 60 patients according to Baveno IV criteria. Excluding the criterion of "transfusion of 2 units of blood or more (over and above the previous transfusions)" and ABRI criterion, failure to control variceal bleeding was observed in 17 and 14 of 60 patients, respectively. Congruence of ABRI with other criteria was present in about two-thirds of the cases. ABRI> or =0.75 was associated with increased risk of positive other Baveno criteria, particularly modified Baveno II-III (odds ratio [OR] 4.10; 95% confidence interval [CI], 1.11-15.05) and Baveno IV without ABRI (OR 4.37; 95% CI, 1.04-18.28). Independent predictors of ABRI> or =0.75 identified in logistic regression analysis were male sex (P<0.001) and higher hematocrit values (P=0.004). CONCLUSION We found low congruence between ABRI and other Baveno criteria and the incidence of treatment failure in our study was higher than the previously reported frequencies of early rebleeding. It seems that criteria related to the quantity of blood transfusions are not reliable indicators of treatment failure.
Collapse
Affiliation(s)
- Marko Duvnjak
- Department of Medicine, Division of Gastroenterology and Hepatology, Sestre milosrdnice University Hospital, Vinogradska cesta 29 10000 Zagreb, Croatia.
| | | | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- Davor Hrabar
- Department of Gastroenterology and Hepatology, Sestre Milosrdnice University Hospital, Zagreb, Croatia
| | | | | | | | | | | |
Collapse
|
38
|
Duvnjak M, Lerotić I, Tomasić V, Pavić T, Virović L. [Inflammatory bowel disease and pregnancy]. Lijec Vjesn 2006; 128:48-55. [PMID: 16640228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Inflammatory bowel diseases (IBD) can affect women of childbearing potential. There are many issues to consider in female patients with IBD who are contemplating pregnancy, such as influence of the disease on fertility or pregnancy outcome, effect of the gestation on the course of the disease, safety of the drugs and inheritance of the disease in the offspring. It is important to remember that the outcome of the pregnancy is dependent mostly on the activity of the disease at the time of conception and there is no increase of the adverse events in patients with quiescent bowel disease. With few exceptions, majority of medications used in the treatment of IBD are safely used during pregnancy and breastfeeding. This article reviews the most recent knowledge regarding the effects of IBD and their treatment on fertility and pregnancy, therapeutic options and outcomes in patients who are planning pregnancy or who are pregnant or lactating.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica Sestre milosrdnice, Zagreb
| | | | | | | | | |
Collapse
|
39
|
Vucelić B, Hrstić I, Begovac J, Bradarić N, Burek V, Colić-Cvrlje V, Duvnjak M, Kekez AJ, Kes P, Lesnikar V, Mise S, Morović M, Ostojić R, Pavić I, Stimac D, Vcev A, Vince A. [Viral hepatitis: Croatian consensus statement]. Acta Med Croatica 2005; 59:359-75. [PMID: 16381229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
There has been a dramatic improvement in diagnostic procedures and therapy of viral hepatitis in the last 20 years. Improvements in therapy caused an increase in actual cost, however, with significant long-term savings through a decreased cost of treatment of advanced liver disease including liver transplantation. The Croatian National Board for Viral Hepatitis has decided to initiate the organization of consensus conference on viral hepatitis enabling the leading experts in the country to give the best possible recommendations for the diagnosis, prophylaxis and therapy in our circumstances. The Consensus Conference took place in Zagreb in June 2004, with update in March 2005, organized by the Croatian National Board for Viral Hepatitis, Reference Centers of the Ministry of Health for Chronic Liver Diseases, Infectious Diseases and AIDS, Croatian Society of Gastroenterology--Hepatology Section, Croatian Society for Nephrology, Dialysis and Transplantation, and Croatian Institute for Health Insurance. Invited experts provided written reports on the respective subjects that appear in this issue and their recommendations resulting in this consensus statement.
Collapse
Affiliation(s)
- Boris Vucelić
- Zavod za gastroenterologiju, Klinika za unutrasnje bolesti, Klinicki bolnicki centar Zagreb, Kispatićeva 12, 10000 Zagreb, Hrvatska.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Duvnjak M, Pavić T, Tomasić V, Lerotić I, Virović L. [Hepatitis C--treatment of untreated (naive) patients]. Acta Med Croatica 2005; 59:453-61. [PMID: 16381243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
The most important therapeutic advance in recent years considering chronic HCV infection has occurred with the introduction of pegylated interferon (PEG IFN) in the combination therapy with ribavirin, which results in better sustained virologic response (SVR). Although an SVR is difficult to correlate with improved survival because of the necessity for long-term follow up, the absence of detectable serum HCV RNA has been associated with resolution of liver injury, reduction in hepatic fibrosis, and a low likelihood of a relapse of the HCV infection. Two large pivotal trials examined the efficacy of PEG IFN plus ribavirin in the treatment of chronic HCV infection. Overall, PEG IFN plus ribavirin was more effective than the standard interferon-ribavirin combination. SVR rates were similar with both forms of PEG IFN (PEG IFN alfa-2a and PEG IFN alfa-2b) when used in combination with ribavirin. SVR rates of 42% and 46% were achieved in patients with genotype 1 compared to rates of 76% and 82% in patients with genotypes 2 and 3. Factors associated with successful therapy included genotypes other than 1, lower baseline viral levels, less fibrosis or inflammation on liver biopsy, and lower body weight or body surface area. Twenty four weeks of treatment with a combination of PEG IFN and ribavirin appears to be sufficient for patients infected with genotypes 2 and 3, while patients with genotype 1 need 48 weeks of treatment. Early virologic response (EVR), defined as undetectable HCV RNA or a minimum 2 log decrease in viral load (relative to baseline) after the first 12 weeks of treatment, is predictive of SVR and should be a routine part of monitoring patients with genotype 1. Patients who fail to achieve an EVR have only a small chance of achieving an SVR, therefore treatment should be discontinued after 12 weeks. It is also recommended to treat patients with acute hepatitis C to reduce the risk of developing chronic infection. Treatment should start 12 weeks after the onset of symptoms and includes 24 weeks of monotherapy with PEG IFN.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska.
| | | | | | | | | |
Collapse
|
41
|
Duvnjak M, Virović L. [Gastrointestinal complications in treatment with classical nonsteroidal antirheumatic agents]. Reumatizam 2003; 49:24-5. [PMID: 12476756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
The most frequent gastro-intestinal complications in classical NSAID treatment are presented. Nausea and dispepsy are present in 60 percent, and gastric erosions in 50 percent of patients on regular NSAID treatment. COX-2 inhibitors with lower rate of gastro-intestinal complications are mentioned.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica Sestre milosrdnice, Vuinogradska 29, 10000 Zagreb
| | | |
Collapse
|
42
|
Duvnjak M, Supanc V, Virović L, Tomasić V, Dojcinović B. [Caroli's disease]. Acta Med Croatica 2003; 57:249-52. [PMID: 14582472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Caroli's disease is a rare condition characterized by congenital polycystic dilatation of the intrahepatic bile ducts. The most frequent clinical presentation of a simple type (Caroli's disease) is recurrent cholangitis, gallstone with pain, obstructive jaundice and episodes of pancreatitis in childhood and early adulthood. A more frequent type combined with congenital hepatic fibrosis is usually manifested with bleeding from esophageal varices consequential to portal hypertension. Treatment options, both conservative and surgical, are relatively limited and depend on the clinical presentation, localization of cysts in the liver, and stage of the disease. A 20-year-old man with Caroli's disease manifested with cholelithiasis and choledocholithiasis with recurrent pancreatitis at the age of 16 is presented. The diagnosis was confirmed by endoscopic retrograde cholangiopancreatography and magnetic resonance cholangiopancreatography. Treatment with ursodeoxycholic acid was initiated and after two years of follow-up the disease is stable.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti Klinicke bolnice Sestre milosrdnice, 10000 Zagreb, Hrvatska.
| | | | | | | | | |
Collapse
|
43
|
Duvnjak M. [Advances in the treatment of chronic viral hepatitis]. Acta Med Croatica 2003; 57:157. [PMID: 14582460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
|
44
|
Virović L, Supanc V, Duvnjak M. [Primary sclerosing cholangitis--diagnosis and therapy]. Acta Med Croatica 2003; 57:207-19. [PMID: 14582467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin, characterized by inflammation, fibrosis, and obliteration of bile ducts, which ultimately results in biliary cirrhosis. The condition most commonly affects intrahepatic and extrahepatic bile ducts together, but sometimes only intrahepatic or extrahepatic ducts are involved. PSC is often associated with inflammatory bowel disease, especially ulcerative colitis. The majority of patients are initially asymptomatic, and identified on the basis of elevated serum levels of alkaline phosphatase or gamma-glutamyl transpeptidase, especially while screening patients with ulcerative colitis. Diagnosis is based on characteristic cholangiographic appearance with focal bile duct dilatations proximal to areas of stricturing that produce a beaded appearance. Ursodeoxycholic acid is most effective medical therapy, with other symptomatic measures, while liver transplantation is the treatment of choice for patients with advanced liver disease.
Collapse
Affiliation(s)
- Lucija Virović
- Zavod za gastroenterologiju i hepatologiju Klinika za unutarnje bolesti Klinicka bolnica Sestre milosrdnice Vinogradska 29, 10000 Zagreb, Hrvatska.
| | | | | |
Collapse
|
45
|
Duvnjak M, Pavić T, Virović L, Hrabar D. [Therapy with interferon alfa and ribavirin in patients with chronic hepatitis C and normal levels of alanine aminotransferase]. Acta Med Croatica 2003; 57:159-62. [PMID: 14582461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
The aim of the study was to evaluate the efficacy of combination therapy with interferon-alpha (IFN-alpha) and ribavirin in patients with chronic hepatitis C and normal alanine aminotransferase (ALT) values. In this retrospective study, 12 HCV-RNA positive patients (7 males and 5 females, mean age 38.1 years), treated between 1998 and 2001, with normal or near normal ALT values on three consecutive occasions and histologically mild disease were identified. During the induction period of four weeks they received 56 MU IFN-alpha 2b and ribavirin 1000 mg daily. During the next 44 weeks they received 3 MU IFN-alpha 2b three times a week with ribavirin 1000 mg daily. Seven out of 12 (58%) patients were HCV-RNA negative at the end of the therapy (end-of-treatment-response) and 5 of 12 (42%) showed sustained virologic response at 6 months. No significant elevation of aminotransferase values was recorded during therapy. Patients with mild chronic hepatitis C and normal ALT levels respond well to combination therapy with interferon and ribavirin, similar to those with elevated ALT levels. As long as the natural history and long-term outcome of these patients are not completely known, this might be a beneficial treatment option.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica Sestre milosrdnice, 10000 Zagreb, Hrvatska.
| | | | | | | |
Collapse
|
46
|
Duvnjak M, Virović L. [Non-alcoholic steatohepatitis]. Acta Med Croatica 2003; 57:189-99. [PMID: 14582465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Nonalcoholic steatohepatitis (NASH) is a condition characterized histologically by macrovesicular steatosis and lobular hepatitis with necrosis or ballooning degeneration and/or fibrosis--a picture resembling alcoholic hepatitis, in the absence of alcohol abuse. Most patients with NASH are asymptomatic, and the disease is detected incidentally. The most common signs of NASH are hepatomegaly and laboratory abnormalities, which include a 2-4-fold elevation of serum aminotransferase levels, while other liver function test results are usually normal. Most patients with NASH are obese, many have diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia. NASH has also been associated with a number of metabolic derrangements, conditions, surgical procedures, and drug treatments. The pathogenesis of NASH is poorly understood, but lipid peroxidation and oxidative stress seem to be the leading culprits. The natural history of NASH is unknown, but it seems to be a stable disease in most patients. Still, the progress to cirrhosis is possible. There is no established treatment for NASH. Treatment is usually directed towards optimizing body weight, and pharmacologic agents are mostly experimentally used. Orthotopic liver transplantation is the treatment of choice for end-stage liver disease secondary to NASH.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju Klinika za unutarnje bolesti Klinicka bolnica Sestre milosrdnice Vinogradska 29, 10000 Zagreb, Hrvatska
| | | |
Collapse
|
47
|
Duvnjak M, Virovic L. [Clinical features and diagnosis of inflammatory bowel disease]. Med Arh 2002; 56:33-6. [PMID: 12055722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The inflammatory bowel disease is common term for heterogenous group of the chronic recidivant idiopathic diseases with bowel inflammation as a common sign. Although within common term, traditionally we distinguish two diseases, Chrohns disease (CD) and ulcerative colitis (UC), in certain clinical situations those terms are not sufficient to describe all variants of inflammatory bowel diseases. Today increasingly, we have more and more knowledge about clinical, immunological, genetical heterogenicity in Crohns disease and ulcerative colitis. New evidences advocate theory that IBD represents folding subgroups of inflammatory bowel disorders in particular continuity with CD and UC as extremes of one spectrum.
Collapse
Affiliation(s)
- Marko Duvnjak
- Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica Sestre milosrdnice, Zagreb, Hrvatska
| | | |
Collapse
|
48
|
Antoljak N, Topić E, Duvnjak M, Vrkić N, Zuntar I. Hepatocyte growth factor levels in Croatian healthy and alcoholic liver cirrhosis patients. Coll Antropol 2001; 25:341-8. [PMID: 11787560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Hepatocyte growth factor (HGF) is a most potent hepatocyte mitogen, and plays a mayor role in liver regeneration during injury. The aim of this study was to evaluate HGF values in Croatian healthy and alcoholic liver cirrhosis patients (AC). The HGF and standard laboratory tests of liver damage were measured in 33 AC patients, and 41 healthy subjects. HGF was measured by using an ELISA method. The HGF levels were higher in cirrhotic patients than in healthy subjects (median value is 0.78 vs. 0.19 ng/ml, p < 0.001). Japanese study showed similar values of HGF for healthy subjects and AC subjects. The HGF values in patients depend on grade of illness. There was found significant correlation between HGF and almost all standard liver damage tests. The ROC analysis showed that measuring of HGF had convincingly best accuracy than other parameters, and seems to be useful in classifying grade of illness.
Collapse
Affiliation(s)
- N Antoljak
- Clinical Institute of Chemistry, Sestre milosrdnice University Hospital, Zagreb, Croatia
| | | | | | | | | |
Collapse
|
49
|
Duvnjak M, Pavic T, Goranovic T. Perforation--a rare complication of a small-bowel carcinoid. Eur J Gastroenterol Hepatol 2000; 12:807-8. [PMID: 10929910 DOI: 10.1097/00042737-200012070-00015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
Carcinoids are rare compared to other tumours of the gastrointestinal tract, but present a significant portion of tumours of the small intestine. The case of a 50-year-old man who suffered perforation of a small-bowel carcinoid after failed diagnostic trials is reported here. Since intestinal perforation is rarely the first sign of the presence of a carcinoid, it is useful to bear this in mind when dealing with unclear pathological changes of the small intestine.
Collapse
Affiliation(s)
- M Duvnjak
- Department of Gastroenterology and Hepatology, University Hospital Sestre Milosrdnice, Zagreb, Croatia
| | | | | |
Collapse
|
50
|
Duvnjak M, Supanc V, Simicević VN, Hrabar D, Troskot B, Smircić-Duvnjak L, Bekavac-Beslin M. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica 2000; 53:115-8. [PMID: 10705631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Acute pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterectomy (EST). In addition, serum pancreatic enzymes increase without clinical symptoms in up to 75% of patients undergoing endoscopic procedures. The aim of this trial was to investigate the effects of octreotide in the prevention of these possible complications in patients undergoing therapeutic ERCP. The study was carried out in 209 subjects who were randomly allocated to two groups (A and B). Group A received 0.5 mg of octreotide-acetate subcutaneously one hour prior to ERCP; group B was given placebo. Serum amylase and lipase values were measured before premedication and 1.5, 2, 6 and 24 hours following endoscopy. Following ERCP, the increase in both amylase and lipase values was significantly greater in the control (placebo) group, but this significance disappeared 24 hours following the procedure. Symptoms of acute pancreatitis developed in 4 (3.85%) patients who were given octreotide-acetate, compared to 10 (9.52%) patients in the control group. The results obtained in our study seem to indicate that octreotide could prevent the increase in serum pancreatic enzymes, but no significant difference was observed in the prevention of post-ERCP pancreatitis.
Collapse
Affiliation(s)
- M Duvnjak
- Department of Gastroenterology and Hepatology, Sestre Milosrdnice University Hospital, Zagreb, Croatia
| | | | | | | | | | | | | |
Collapse
|